Powerhouse Podcast #35: UMDF Team Activate 2024
Powerhouse Podcast #35: UMDF Team Activate 2024 & the Bank of America Chicago Marathon On this November’s Powerhouse Podcast episode,...
Read moreLatest News
UMDF November Advocacy Update: What Does a Second Trump Administration Mean for the Mito Community?
With the recent election results, we’ve been getting some inquiries about the impact of a second Trump Administration on mitochondrial disease...
Read moreAsk the Mito Doc – November 2024; Q&A
Ask the Mito Doc – November 2024 Q&A All answers today are based on personal experience of the participants. As always, please...
Read moreThe Mito Fund Announces Investment in Khondrion to Support Development of One of the Most Advanced Drug Candidates for Primary Mitochondrial Disease
The United Mitochondrial Disease Foundation’s (UMDF) venture philanthropy arm, The Mito Fund, has invested in Khondrion, a Netherlands-based...
Read moreUMDF Cosigns Letter to Congress Encouraging End-of-Year Rare Disease Legislative Priorities
UMDF Cosigns Letter to Congress Encouraging End-of-Year Action on Accelerating Kids’ Access to Care Act, Rare Pediatric Disease Priority Review...
Read moreNovember 2024 Newsletter: FDA News, Rare Revolution Magazine Feature, Therapeutic Pipeline Updates, and more
Sign-up to receive the UMDF newsletter via email at Newsletter Signup. In early October, an FDA Advisory Committee voted 10-6 supporting...
Read moreAsk the Mito Doc – October 2024; Q&A
Ask the Mito Doc – October 2024 Q&A All answers today are based on personal experience of the participants. As always, please...
Read morePowerhouse Podcast #34: Olivia Chambers
Powerhouse Podcast #34: Olivia Chambers This month, we meet with Olivia Chambers, a college athlete at the University of Northern Iowa. She...
Read moreAdvocacy Update – Oct 2024: FDA AdComm Brings Good News, Plus DC End of Year Business
FDA Advisory Committee Deems Potential Barth Syndrome Drug “Effective” Earlier this month, an FDA Advisory Committee voted 10-6...
Read moreUMDF Reacts to FDA Advisory Committee’s Elamipretide Recommendation
After a full day of testimony that consistently demonstrated the need and efficacy of elamipretide for the treatment of Barth Syndrome, an FDA...
Read more